Kidney Cancer: CTSU E2805 (Hematology Oncology Associates)

CTSU E2805: ASSURE--Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma.


This research is being done because there is no effective therapy to prevent
recurrence of kidney cancer.

The purpose of this study is to determine if either sunitinib or sorafenib can prevent recurrence of kidney cancer better than placebo alone. The study will also compare the effects (both good and bad) of the sunitinib and the sorafenib with placebo (pills that look like study drugs, but are inactive or do not contain the drug) on patients with kidney cancer to see which is better. It is not known whether the benefits of taking either sunitinib or sorafenib will outweigh the risks.

Sorafenib and sunitinib are drugs which have been approved by the FDA for use in treating advanced kidney cancer but not in the setting of kidney cancer which has been completely removed. The standard treatment for kidney cancer, that has been removed, is observation.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Kidney Cancer
Cancer Trials Support Unit
Katy D'Aprile, RN, BSN at 563-355-7733


  • University of Iowa Hospital & Clinics, Cancer Center of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office